Antiviral Phosphonate Synthesis Using Biphasic Phase-Transfer Catalysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthesis methods for the compound (((1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(phenoxy)phosphoryloxy)methyl pivalate suffer from the use of hazardous solvents like N-methyl pyrrolidone, low yields, and difficulty in removing impurities, making them unsuitable for large-scale industrial production.
Innovation Solution
A new synthesis process using triphenylphosphite and a phase transfer catalyst in a biphasic solvent system, followed by conversion to a pharmaceutically acceptable salt, reduces solvent hazards and improves yield, achieving high diastereomeric purity and low residual solvent content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If N-methyl pyrrolidone is used as solvent in the synthesis steps, then the reaction can proceed, but the solvent is hazardous to human and environment, high boiling point makes it difficult to remove completely, and increases process complexity
Solution Approach 1:
The patent changes the solvent parameters by replacing N-methyl pyrrolidone with alternative solvents such as dichloromethane, ethyl acetate, or their mixtures. This substitution maintains reaction effectiveness while eliminating the hazardous properties and high boiling point issues of the original solvent, making removal and processing much easier.
Solution Approach 2:
The patent employs solvents that are easier to dispose of and remove compared to N-methyl pyrrolidone. The alternative solvents can be more readily evaporated or separated, reducing the need for complex removal processes and making the overall manufacturing easier.
2Productivity
If the literature procedure is used for synthesis, then the compound can be prepared, but the yield is low and reaction conversion is inconsistent
Solution Approach 1:
The patent implements quality by design approach with controlled reaction conditions, monitoring and optimization steps that ensure consistent conversion. The process includes specific temperature ranges, stoichiometric ratios, and purification steps that provide feedback control to maintain reliable and reproducible reaction outcomes across different scales.
Solution Approach 2:
The patent optimizes reaction parameters including temperature, solvent composition, catalyst loading, and reaction time to achieve both high yield and consistent conversion. The modified procedure uses optimized conditions that improve upon the literature method, ensuring reliable scalability.
3Quantity of substance
If the synthesis is scaled up using the existing method, then production quantity increases, but the efficiency decreases due to solvent hazards, low yield, and impurity removal difficulties
Solution Approach 1:
The patent segments the synthesis into optimized discrete steps with intermediate purification and salt formation. This segmentation allows each step to be independently optimized and controlled, maintaining high efficiency even at large scale. The process includes isolation of intermediate compounds and controlled conversion to final salt forms, ensuring quality and efficiency throughout scale-up.
Solution Approach 2:
The patent modifies multiple process parameters simultaneously - solvent system, temperature profiles, reaction stoichiometry, and purification conditions - to create a scalable process that maintains high efficiency. The optimized parameters ensure that yield and purity are maintained regardless of production quantity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high yields and purity, with the final product having over 95% purity, making it suitable for industrial scale-up and effective in treating diseases like HIV and AIDS by inhibiting nucleotide reverse transcriptase activity.
Implementation Method 1
reacting a compound of Formula (2) with triphenylphosphite in the presence of a base, and a solvent to form a compound of Formula (3)
Implementation Method 2
reacting the compound of Formula (3) with chloromethyl pivalate in the presence of a phase transfer catalyst, a base and a solvent to form a compound of Formula (4)
Data Source
AI summary
The present invention relates to an improved process for the preparation of (((1-(6-amino-9H-purin-9-yl)propan-2-yloxy)methyl)(phenoxy)phosphoryloxy)methyl pivalate Compound (1) or its pharmaceutically acceptable salts thereof. The compound is useful as nucleotide reverse transcriptase inhibitor in therapy for diseases which respond to inhibition of protein kinase activity in humans in need thereof.